Chris Howerton

Immunomedics, Inc. (NASDAQ: IMMU) stock, which has been on a broader upward trajectory since FDA approved its lead asset Trodelvy, has further room to run, according to a Jefferies analyst.  The Immunomedics Analyst: Chris Howerton reiterated a Buy rating on Immunomedics and...